Prehospital tirofiban increases the rate of disrupted myocardial infarction in patients with ST-segment elevation myocardial infarction: insights from the On-TIME 2 trial
Primary result · Disrupted MIResult — go to the resultOdds ratio 2.03 95% CI 1.10–3.87Authors' conclusion
Among STEMI patients undergoing primary PCI, the use of prehospital tirofiban was independently associated with a higher rate of disrupted MI.
Study context
- Population
- STEMI patients undergoing primary percutaneous coronary intervention (PCI) with measured high-sensitivity cardiac troponin (hs-cTn) levels
- Participants
- 786 patients
- Comparison
- Prehospital tirofiban vs placebo
- Tirofibann = 386
- Placebon = 400reference
- Primary endpoint
- Disrupted MI (peak hs-cTn T ≤10 times upper limit of normal, ≤140 ng/L)
- Follow-up
- 18-24 and 72-96 h after PCI
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
Disrupted MI
Odds ratio
2.03
95% CI 1.10–3.87
P = 0.027
Events by treatment group
Tirofibanvs Placebo
OR 2.03 (95% CI 1.10–3.87); P = 0.027
As reported in the abstract
Further findings
| Outcome | Disrupted MI | No disrupted MI |
|---|---|---|
| 1-year mortality, disrupted MI vs no disrupted MI | 0 events | 2.6% |
- 1-year mortality, disrupted myocardial infarction (MI) vs no disrupted MI: overall 47 (6%) had disrupted MI
Original publication
Prehospital tirofiban increases the rate of disrupted myocardial infarction in patients with ST-segment elevation myocardial infarction: insights from the On-TIME 2 trial. Eur Heart J Acute Cardiovasc Care. Published 7 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →